IS6810A - Samsetningar af N-(metýletýlamínókarbónýl)-4-(3-metýlfenýlamínó)-3-pýridýl-súlfonamíði og hringlagafásykrum - Google Patents

Samsetningar af N-(metýletýlamínókarbónýl)-4-(3-metýlfenýlamínó)-3-pýridýl-súlfonamíði og hringlagafásykrum

Info

Publication number
IS6810A
IS6810A IS6810A IS6810A IS6810A IS 6810 A IS6810 A IS 6810A IS 6810 A IS6810 A IS 6810A IS 6810 A IS6810 A IS 6810A IS 6810 A IS6810 A IS 6810A
Authority
IS
Iceland
Prior art keywords
methylethylaminocarbonyl
methylphenylamino
sulfonamide
pyridyl
combinations
Prior art date
Application number
IS6810A
Other languages
English (en)
Inventor
Dumic Miljenko
Filic Darko
Klepic Bozena
Danilovski Aleksandar
Tudja Marijan
Original Assignee
Pliva, Farmaceutska Industrija, Dionicko Drustvo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva, Farmaceutska Industrija, Dionicko Drustvo filed Critical Pliva, Farmaceutska Industrija, Dionicko Drustvo
Publication of IS6810A publication Critical patent/IS6810A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IS6810A 2000-11-10 2003-05-08 Samsetningar af N-(metýletýlamínókarbónýl)-4-(3-metýlfenýlamínó)-3-pýridýl-súlfonamíði og hringlagafásykrum IS6810A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000765A HRP20000765A2 (en) 2000-11-10 2000-11-10 Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
PCT/HR2001/000004 WO2002038186A1 (en) 2000-11-10 2001-01-31 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides

Publications (1)

Publication Number Publication Date
IS6810A true IS6810A (is) 2003-05-08

Family

ID=10947206

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6810A IS6810A (is) 2000-11-10 2003-05-08 Samsetningar af N-(metýletýlamínókarbónýl)-4-(3-metýlfenýlamínó)-3-pýridýl-súlfonamíði og hringlagafásykrum

Country Status (26)

Country Link
US (1) US7037928B2 (is)
EP (1) EP1347780B1 (is)
JP (1) JP2004513155A (is)
KR (1) KR20030060929A (is)
CN (1) CN1477977A (is)
AR (1) AR026815A1 (is)
AU (1) AU2001228721A1 (is)
BG (1) BG107896A (is)
BR (1) BR0115281A (is)
CA (1) CA2428179A1 (is)
CZ (1) CZ20031490A3 (is)
DE (1) DE60125828T2 (is)
EA (1) EA005111B1 (is)
EE (1) EE200300197A (is)
GE (1) GEP20043403B (is)
HR (1) HRP20000765A2 (is)
HU (1) HUP0400776A2 (is)
IL (1) IL155818A0 (is)
IS (1) IS6810A (is)
MX (1) MXPA03004111A (is)
NO (1) NO20032091L (is)
PL (1) PL361667A1 (is)
SK (1) SK6722003A3 (is)
WO (1) WO2002038186A1 (is)
YU (1) YU35303A (is)
ZA (1) ZA200303601B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
DE602005002930T2 (de) * 2004-01-22 2008-07-24 Pfizer Inc. Sulfonamidderivate zur behandlung von krankheiten
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
EP2591783A1 (en) 2007-04-13 2013-05-15 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
BR102012009317B1 (pt) * 2012-04-20 2022-05-31 Universidade Federal De Minas Gerais - Ufmg Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
WO2020141224A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906020A1 (en) * 2019-01-04 2021-11-10 SQ Innovation AG Pharmaceutical compositions of torsemide and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576511A (en) * 1897-02-02 Georg steinike and friedrich schmidt
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
WO1997021312A2 (en) * 1995-12-01 1997-06-12 Philips Electronics N.V. A digital cordless telephony system, a radio base station, and a combination of a radio base station and a cordless handset
US6828334B2 (en) * 2002-05-23 2004-12-07 Usv Limited Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition

Also Published As

Publication number Publication date
NO20032091D0 (no) 2003-05-09
PL361667A1 (en) 2004-10-04
KR20030060929A (ko) 2003-07-16
GEP20043403B (en) 2004-06-10
EP1347780B1 (en) 2007-01-03
EA200300556A1 (ru) 2003-08-28
DE60125828D1 (de) 2007-02-15
MXPA03004111A (es) 2004-05-05
JP2004513155A (ja) 2004-04-30
BG107896A (bg) 2004-01-30
DE60125828T2 (de) 2007-08-16
HUP0400776A2 (hu) 2004-08-30
CA2428179A1 (en) 2002-05-16
YU35303A (sh) 2006-03-03
ZA200303601B (en) 2004-07-19
CZ20031490A3 (cs) 2003-08-13
EE200300197A (et) 2003-08-15
EA005111B1 (ru) 2004-10-28
WO2002038186A1 (en) 2002-05-16
HRP20000765A2 (en) 2002-06-30
BR0115281A (pt) 2003-07-29
AU2001228721A1 (en) 2002-05-21
US20040039204A1 (en) 2004-02-26
IL155818A0 (en) 2003-12-23
SK6722003A3 (en) 2003-10-07
US7037928B2 (en) 2006-05-02
CN1477977A (zh) 2004-02-25
EP1347780A1 (en) 2003-10-01
NO20032091L (no) 2003-07-02
AR026815A1 (es) 2003-02-26

Similar Documents

Publication Publication Date Title
DK1404809T3 (da) Forbedrede hudsubstitutter og anvendelser deraf
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20024742D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20024355L (no) Nukleosidforbindelser og anvendelser derav
DK1372767T3 (da) Forbedring af og relaterende til en injektionsanordning
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
FR2818646B1 (fr) Nouveaux derives c-glycoside et utilisation
NO20011964D0 (no) Brönnbehandlingsfluider og fremgangsmåter med anvendelse derav
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
DK1370128T3 (da) Kombineret ballepresse og ballevikler
DK1495053T3 (da) Angiopoietin-2 og angiopoietin-1-specifikke bindemidler
DK1202941T3 (da) Gipssammensætninger og beslægtede fremgangsmåder
NO20030832D0 (no) Kondenserte cykliske forbindelser og medisinsk anvendelse derav
DK1227088T3 (da) Krystallinsk base af citalopram og hydrochlorid- eller hydrobromidsaltet deraf
DE60132108D1 (de) Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion
DK1339292T3 (da) Sammensætning og fremgangsmåde
DK1328475T3 (da) Zeolitter og deres anvendelse
DK1216046T3 (da) Hidtil ukendt kombination af loteprednol og antihistaminer
DK1263745T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiaxol-2-oner og anvendelse deraf til inhibering af hormonfölsom lipase
DK1411923T3 (da) Farmaceutisk sammensætning af amlodipin og atorvastatin
NO20021786L (no) Skumdempningsfremgangsmåter og sammensetninger
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20030882D0 (no) Glasskeramikkmasse og anvendelse derav
IS6810A (is) Samsetningar af N-(metýletýlamínókarbónýl)-4-(3-metýlfenýlamínó)-3-pýridýl-súlfonamíði og hringlagafásykrum
DK1499729T5 (da) Derivater af det NF-kappab-inducerende enzym, fremstilling og anvendelse deraf